COR2ED - Oncology Medical Conversation

• Tackling mPDAC: chemotherapy strategies that matter

  Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.    This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.  Key clinical takeaways:  mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles Choice of 2nd line treatment should be guided by prior regimen and patient fitness Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0  Or watch on YouTube: https://youtu.be/8YxRnjOYUv4  Follow us on social media:  LinkedIn: https://www.linkedin.com/company/giconnect  X: https://x.com/giconnectInfo  This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Ipsen USA.  This podcast is developed by cor2ed.com  Published May 2025  Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

  --------  

  21:51

  --------

  21:51
• Understanding Rare NSCLC Mutations: Insights, access and support

  Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.    As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.    Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.  What does the patient pathway look like from both perspectives?  What are the needs of Medical Oncologists and patients when navigating the treatment journey?  What do patients need from their oncologists?  What do oncologists think their patients need from them?  Are these needs matched by the support currently available?    You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0  Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t    Follow LUNG CONNECT on social media:  X – https://x.com/lung_connect   LinkedIn – https://www.linkedin.com/company/lungconnect/   This content is intended for healthcare professionals only.  The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.    This podcast is developed by cor2ed.com  Published on May 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

  --------  

  20:34

  --------

  20:34
• The HER2 diagnostic and treatment landscape in NSCLC

  Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.    In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.  The conversation unfolds to cover;  How to distinguish HER2 alterations from other alterations on biomarker reports  The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC   The potential CNS activity of these treatments in patients with HER2-mutated NSCLC  How the treatment pathway may look in the near future  You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/ Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y   Follow LUNG CONNECT on social media:  X – https://x.com/lung_connect   LinkedIn – https://www.linkedin.com/company/lungconnect/   This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer.    This podcast is developed by cor2ed.com  Published on May 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

  --------  

  18:36

  --------

  18:36
• The HER2 Diagnostic and Treatment Landscape in NSCLC

  Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.    What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos.  In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting.  Listen to different expert perspectives on  The different HER2 alterations and prevalence in NSCLC  Which technique to identify which HER2 alteration  HER2-targeted treatments, both approved and in development    You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1  Or watch on YouTube: https://youtu.be/3vMCzR1jqbI    Follow LUNG CONNECT on social media:  X – https://x.com/lung_connect   LinkedIn – https://www.linkedin.com/company/lungconnect/     This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer.    This podcast is developed by cor2ed.com  Published on April 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

  --------  

  21:27

  --------

  21:27
• ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses

  In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.  Key topics include  Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET  Clinical implications of the EMERALD subgroup analyses  Review of elacestrant's safety profile       Clinical takeaways  Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer  The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N  Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors  These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression    This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.    This video was developed by https://cor2ed.com/      Published March 2025 

  --------  

  13:43

  --------

  13:43

Plus de podcasts Éducation

Podcasts tendance de Éducation

À propos de COR2ED - Oncology Medical Conversation

COR2ED - Oncology Medical Conversation: Podcasts du groupe